Methods and compositions for treatment of epileptic disorders
Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
1. A method of treating status epilepticus comprising administering to a patient in need thereof a pharmaceutical composition comprising ganaxolone or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the patient is administered ganaxolone or a pharmaceutically acceptable salt thereof twice daily.
3. The method of claim 1 , wherein the patient is administered ganaxolone or a pharmaceutically acceptable salt thereof three times daily.
4. The method of claim 1 , wherein the pharmaceutical composition is an oral suspension.
5. The method of claim 1 , wherein the pharmaceutical composition is an oral capsule.
6. The method of claim 4 , wherein the patient is administered ganaxolone or a pharmaceutically acceptable salt thereof in an amount of up to 1,800 mg/day.
7. The method of claim 1 , wherein the pharmaceutical composition is an oral suspension comprising 50 mg/ml ganaxolone or a pharmaceutically acceptable salt thereof.
8. The method of claim 1 , wherein the pharmaceutical composition is an oral suspension comprising 50 mg/ml ganaxolone or a pharmaceutically acceptable salt thereof and is administered three times daily.
9. The method of claim 1 , wherein the pharmaceutical composition is an oral suspension comprising 50 mg/ml ganaxolone or a pharmaceutically acceptable salt thereof administered three times daily wherein the patient is administered an amount of up to 1,800 mg/day.
10. The method of claim 1 , wherein the patient is administered 600 mg ganaxolone or a pharmaceutically acceptable salt thereof.
11. The method of claim 1 , wherein the patient is administered 600 mg ganaxolone or a pharmaceutically acceptable salt thereof three times daily.
12. The method of claim 1 , wherein the patient is administered 50 mg ganaxolone or a pharmaceutically acceptable salt thereof.
13. The method of claim 1 , wherein the patient is administered 100 mg ganaxolone or a pharmaceutically acceptable salt thereof.
14. The method of claim 1 , wherein the patient is administered 200 mg ganaxolone or a pharmaceutically acceptable salt thereof.
15. The method of claim 1 , wherein the patient is administered 300 mg ganaxolone or a pharmaceutically acceptable salt thereof.
16. The method of claim 1 , wherein the patient is administered 400 mg ganaxolone or a pharmaceutically acceptable salt thereof.
17. The method of claim 1 , wherein the patient is administered 500 mg ganaxolone or a pharmaceutically acceptable salt thereof.
18. The method of claim 1 , wherein the patient is administered oral capsules comprising 200-600 mg ganaxolone or a pharmaceutically acceptable salt thereof.
19. The method of claim 1 , wherein the pharmaceutical composition provides reduction in the frequency of seizures.
20. The method of claim 1 , wherein the pharmaceutical composition provides reduction in the frequency of seizures, the severity of seizures, or a combination thereof.
21. A method of treating status epilepticus comprising administering to a patient in need thereof a pharmaceutical composition comprising ganaxolone or a pharmaceutically acceptable salt thereof wherein the pharmaceutical composition is administered intravenously.
22. The method of claim 21 wherein the pharmaceutical composition provides improvement to the patient after administration for more than 8 hours.
23. The method of claim 21 wherein the pharmaceutical composition comprises about 30 mg ganaxolone.
24. The method of claim 21 wherein the patient is administered about 150 mg to 1000 mg/day ganaxolone.
25. The method of claim 21 wherein the patient is administered about 500 mg to 1000 mg/day ganaxolone.
26. The method of claim 21 wherein the patient is administered about 625 mg to 650 mg/day ganaxolone.
27. The method of claim 21 wherein the patient is administered about 650 mg to 675 mg/day ganaxolone.
28. The method of claim 21 wherein the patient is administered about 675 mg to 700 mg/day ganaxolone.
29. The method of claim 21 wherein the patient is administered about 625 mg to 700 mg/day ganaxolone.
30. The method of claim 21 wherein the patient is administered about 700 mg to 725 mg/day ganaxolone.
31. The method of claim 21 wherein the patient is administered about 1025 mg to 1050 mg ganaxolone.